The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Satya Vani Nannapaneni
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Smallcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Satya Vani Nannapaneni, a member of the promoter group of Natco Pharma, sold 45,000 equity shares (face value Rs. 2 each) in the open market on 9 March 2026. This represents about 0.02% of the company's total share capital of 17.91 crore shares. Her holding reduced from 3,79,851 shares (0.21%) to 3,34,851 shares (0.19%). The disclosure was filed under SEBI SAST Regulations 2011 and Form C of the Insider Trading Regulations 2015.
The sale is a minor, routine offloading by an individual promoter group member and is too small (0.02%) to materially affect shareholding pattern or signal any negative intent. Retail investors are unlikely to see any meaningful price impact from this transaction.